Dartmouth-Hitchcock Medical Center
dartmouth-hitchcock.orgTotal trials
480
Active
82
Phase 3
14
Total enrollment
128,645
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intrapleural Saline with possible escalation to intraplerual alteplase and dornase. | — | — | — | — | — | 1 | |
| Lidocaine in Saline | — | — | — | — | — | 1 | |
| Normal saline | — | — | — | 3 | |||
| Tacrolimus | — | — | — | — | — | 1 | |
| cellcept | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | 5 | |||
| Fludarabine | — | — | — | 3 | |||
| G-CSF | — | — | — | — | 3 | ||
| Capecitabine | — | — | — | — | 3 | ||
| Fulvestrant | — | — | — | — | 2 | ||
| Tetrathiomolybdate | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Nab-paclitaxel + Gemcitabine | — | — | — | — | — | 1 | |
| modified FOLFIRINOX | — | — | — | — | — | 1 | |
| Neratinib | — | — | — | — | — | 1 | |
| Alpelisib | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| Abemaciclib | — | — | — | — | — | 1 | |
| Botox 50 Unit | — | — | — | — | — | 1 | |
| Botox 100 Unit | — | — | — | — | — | 1 | |
| Switch | — | — | — | — | — | 1 | |
| Naltrexone | — | — | — | — | — | 1 | |
| Letrozole 2.5mg | — | — | — | — | — | 1 | |
| Estradiol | — | — | — | — | — | 1 | |
| ABY-029 | — | — | — | — | 5 | ||
| Immunofluorescence Imaging | — | — | — | — | — | 1 | |
| Fluorescein injection, USP 10% | — | — | — | — | — | 1 | |
| 5-aminolevulinic acid | — | — | — | — | — | 1 | |
| Ameluz 10% Topical Gel | — | — | — | — | — | 1 |
Next readouts
- 2025-02-14
- 2025-04-02
- 2026-08-05
- 2026-09-01
- 2026-10
- 2026-11
- 2026-12
- 2027-03-01
- 2027-04
- 2027-04-30
Top conditions
- Schizophrenia27
- Breast Cancer26
- Schizoaffective Disorder17
- Depression14
- Bipolar Disorder14
- Obesity13
- Epilepsy12
- Cancer11
Frequently asked questions about Dartmouth-Hitchcock Medical Center
- How many clinical trials does Dartmouth-Hitchcock Medical Center have on ClinicalTrials.gov?
- Dartmouth-Hitchcock Medical Center is listed as the lead sponsor on 480 clinical trials in ClinicalTrials.gov, 82 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Dartmouth-Hitchcock Medical Center's trials are in Phase 3?
- 14 of Dartmouth-Hitchcock Medical Center's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does Dartmouth-Hitchcock Medical Center focus on?
- Dartmouth-Hitchcock Medical Center's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Breast Cancer, Schizoaffective Disorder, Depression, Bipolar Disorder.
- When are Dartmouth-Hitchcock Medical Center's next clinical trial readouts?
- Dartmouth-Hitchcock Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression”, expected around 2025-02-14.